Skip to main content

Table 2 Patient clinical outcomes

From: Calcitonin gene related peptide monoclonal antibody treats headache in patients with active idiopathic intracranial hypertension

  P1 P2 P3 P4 P5 P6 P7 Mean (SD)
MmsHD change at 3 months − 3 − 6 − 9 − 9 − 2 − 6 − 4 − 5.6 (2.8)
p = 0.002
MmsHD change at relapse − 5 − 13 − 6 − 13 − 7 − 10 − 6 −8.6 (3.4)
p < 0.001
MHD change at 3 months − 20 0 − 18 − 12 − 15 −16 − 4 −12.1 (7.4)
p = 0.028
MHD change at relapse − 22 0 0 −15 − 10 − 24 − 5 − 10.9 (9.9)
p = 0.043
Headache severity (NRS) change at 3 months 2 −0.9 0.2 −2.6 0.1 0.1 −1.7 −0.4 (1.5)
p = 0.497
Headache severity (NRS) change at relapse 2.7 −1.4 −0.8 −2.7 − 1.8 − 0.4 −2.4 − 1.0 (1.8)
p = 0.253
Monthly analgesic days change at 3 months 3 −1 − 6 − 18 0 − 4 −9 − 5.0 (7.0)
p = 0.107
Monthly analgesic days change at relapse 0 0 −5 −18 −7 1 −10 −5.6 (6.9)
p = 0.075
HIT-6 score change at 3 months − 5 −11 − 4 − 13 1 − 8 2 − 5.4 (5.7)
p = 0.045
HIT-6 score change at relapse − 5 − 13 −4 −3 0 −18 − 2 −6.4 (6.6)
p = 0.041
Frisén grade at relapse (worst eye) 4 2 3 1 1 1 1 1.9 (1.2)
OCT global average RNFL thickness at relapse worst eye (μm) a 326 b 140 b 174 b 132 c 116 c 151 c 202 c 177.3 (71.4)
p = 0.043
BMI at relapse 31.3 48.5 38.7 38 44.6 36.7 30.5 38.3 (6.5)
p = 0.025
BMI change 0.3 2.3 3.5 0.7 2.5 7.3 1.7 2.6 (2.3)
IIH characteristics at relapse B, T, V B, T B, T, V B, D, T B, D, T B, D, T B, T  
Side effects   CO   HT, I I CO, MC   
  1. Clinical outcomes and changes compared to erenumab initiation and the 30-day pre-treatment period *, p values indicate changes from erenumab initiation and the 30-day pre-treatment period
  2. aHeidelberg Engineering SPECTRALIS, Heidelberg, Germany
  3. bAt 6 months since commencing erenumab
  4. cAt 12 months since commencing erenumab
  5. Abbreviations: P Patient, IIH Idiopathic intracranial hypertension, MmsHD Monthly moderate/severe days, MHD Monthly headache days, NRS Numeric Rating Scale (0 = no pain to 10 = worst imaginable pain), HIT-6 Headache impact test-6, BMI Body mass index, B Blurred vision, D Double vision, T Tinnitus, V Visual obscurations, OCT Optical coherence tomography, RNFL Retinal nerve fiber layer, CO Constipation, HT Hair thinning, I Itch, MC Muscle cramps